nach oben

Erschienen in:

01.08.2015

Assessment of Parkinson’s disease levodopa-induced dyskinesia: a qualitative research study

verfasst von: William R. Lenderking, Sally Mannix, Jennifer Petrillo, Christopher Kenney, Amanda Landrian, Anette-Eleonore Schrag

Erschienen in: Quality of Life Research | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

The 26-item Parkinson disease dyskinesia scale (PDYS-26) was developed to assess the impact of Parkinson’s disease levodopa-induced dyskinesias (PD-LID). The purpose of this qualitative research study was to assess the content validity of the PDYS-26 in an independent sample and to use the findings to suggest a conceptual framework around the impact of PD-LID.

Methods

PD patients experiencing LID and their caregivers were recruited from four US clinical sites. Stage I involved 22 qualitative concept elicitation interviews with patients and caregivers, and 11 qualitative cognitive interviews (CI) with patients about the PDYS-26. The PDYS-26 was modified based on Stage I findings. Stage II consisted of 13 CI on the Modified PDYS.

Results

Forty-six participants were interviewed across both stages of the study. Patient mean age was 67.3 (SD ± 9.55) years; 19 (54.3 %) female; 34 (97.1 %) white. The content validity of the PDYS-26 was generally supported. A revised conceptual framework with three hypothesized domains (body control, activities of daily living, social consequences) was developed. Modifications were made to the PDYS-26 (i.e., emphasizing LID in the instructions; response scale modification; deleting or modifying items), which resulted in the 22-item Modified PDYS.

Conclusions

Stage I and II findings suggested a number of modifications to the scale in order to improve the content validity. Psychometric testing of the revised scale with a larger patient sample is suggested to evaluate item performance, establish scoring, and provide quantitative support for the conceptual framework.

Encarnacion, E. V., & Hauser, R. A. (2008). Levodopa-induced dyskinesias in Parkinson’s disease: Etiology, impact on quality of life, and treatments. European Neurology, 60(2), 57–66. doi:10.1159/000131893.PubMedCrossRef

Thanvi, B., Lo, N., & Robinson, T. (2007). Levodopa-induced dyskinesia in Parkinson’s disease: Clinical features, pathogenesis, prevention and treatment. Postgraduate Medical Journal, 83(980), 384–388. doi:10.1136/pgmj.2006.054759.PubMedCentralPubMedCrossRef

Jankovic, J. (2008). Parkinson’s disease and movement disorders: Moving forward. The Lancet Neurology, 7(1), 9–11. doi:10.1016/S1474-4422(07)70302-2.PubMedCrossRef

Brotchie, J. M., Lee, J., & Venderova, K. (2005). Levodopa-induced dyskinesia in Parkinson’s disease. [Research Support, Non-U.S. Gov’t Review]. Journal of Neural Transmission, 112(3), 359–391. doi:10.1007/s00702-004-0251-7.PubMedCrossRef

Verhagen Metman, L. (2002). Recognition and treatment of response fluctuations in Parkinson’s disease: Review article. Amino Acids, 23(1–3), 141–145. doi:10.1007/s00726-001-0119-1.PubMedCrossRef

Bargiotas, P., & Konitsiotis, S. (2013). Levodopa-induced dyskinesias in Parkinson’s disease: Emerging treatments. Neuropsychiatr Dis Treat, 9, 1605–1617. doi:10.2147/NDT.S36693.PubMedCentralPubMed

Iravani, M. M., & Jenner, P. (2011). Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of Neural Transmission, 118(12), 1661–1690. doi:10.1007/s00702-011-0698-2.PubMedCrossRef

Ostergaard, K., Sunde, N., & Dupont, E. (2002). Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson’s disease and motor fluctuations. [Clinical Trial Research Support, Non-U.S. Gov’t]. Movement Disorders, 17(4), 693–700. doi:10.1002/mds.10188.PubMedCrossRef

Schrag, A., & Quinn, N. (2000). Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. [Research Support, Non-U.S. Gov’t]. Brain, 123(Pt 11), 2297–2305.PubMedCrossRef

10.

Nutt, J. G., Chung, K. A., & Holford, N. H. (2010). Dyskinesia and the antiparkinsonian response always temporally coincide: A retrospective study. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.]. Neurology, 74(15), 1191–1197. doi:10.1212/WNL.0b013e3181d90050.PubMedCentralPubMedCrossRef

11.

Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000). Levodopa motor complications in Parkinson’s disease. [Case Reports Review]. Trends in Neurosciences, 23(10 Suppl), S2–S7.PubMedCrossRef

12.

Colosimo, C., Martinez-Martin, P., Fabbrini, G., Hauser, R. A., Merello, M., Miyasaki, J., et al. (2010). Task force report on scales to assess dyskinesia in Parkinson’s disease: Critique and recommendations. Movement Disorders, 25(9), 1131–1142. doi:10.1002/mds.23072.PubMedCrossRef

13.

Goetz, C. G., Nutt, J. G., & Stebbins, G. T. (2008). The unified dyskinesia rating scale: Presentation and clinimetric profile. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Movement Disorders, 23(16), 2398–2403. doi:10.1002/mds.22341.PubMedCrossRef

14.

Goetz, C. G., Stebbins, G. T., Shale, H. M., Lang, A. E., Chernik, D. A., Chmura, T. A., et al. (1994). Utility of an objective dyskinesia rating scale for Parkinson’s disease: Inter- and intra-rater reliability assessment. [Clinical Trial Research Support, Non-U.S. Gov’t]. Movement Disorders, 9(4), 390–394. doi:10.1002/mds.870090403.PubMedCrossRef

15.

Guy, W. (1976). ECDEU assessment manual for psychopharmacology (revised ed.). Washington, DC: US Department of Health, Education, and Welfare.

16.

Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The PDQ-39: Development and validation of a parkinson’s disease summary index score. Age and Ageing, 26, 353–357.PubMedCrossRef

17.

Katzenschlager, R., Schrag, A., Evans, A., Manson, A., Carroll, C. B., Ottaviani, D., et al. (2007). Quantifying the impact of dyskinesias in PD: The PDYS-26: A patient-based outcome measure. [Research Support, Non-U.S. Gov’t Validation Studies]. Neurology, 69(6), 555–563. doi:10.1212/01.wnl.0000266669.18308.af.PubMedCrossRef

18.

Martinez-Martin, P., Gil-Nagel, A., Gracia, L. M., Gomez, J. B., Martinez-Sarries, J., & Bermejo, F. (1994). Unified Parkinson’s disease rating scale characteristics and structure. The cooperative multicentric group. [Multicenter Study]. Movement Disorders, 9(1), 76–83. doi:10.1002/mds.870090112.PubMedCrossRef

19.

Parkinson’s Study Group (2001). Evidence of dykinesias in pilot, randomized, placebo-controlled trial of remacemide in advanced parkinsons disease. Archives of Neurology, 58, 1660–1668.

20.

Peto, V., Jenkinson, C., & Fitzpatrick, R. (1998). PDQ-39: A review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. Journal of Neurology, 245(Suppl 1), S10–S14.PubMedCrossRef

21.

Goetz, C. G., Stebbins, G. T., Chung, K. A., Hauser, R. A., Miyasaki, J. M., Nicholas, A. P., et al. (2013). Which dyskinesia scale best detects treatment response? [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Movement Disorders, 28(3), 341–346. doi:10.1002/mds.25321.PubMedCrossRef

22.

Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., et al. (2011). Content validity—Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 2—Assessing respondent understanding. Value in Health, 14(8), 978–988. doi:10.1016/j.jval.2011.06.013.PubMedCrossRef

23.

Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., et al. (2011). Content validity—Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–Eliciting concepts for a new PRO instrument. Value in Health, 14(8), 967–977. doi:10.1016/j.jval.2011.06.014.PubMedCrossRef

24.

Willis, G. B. (2005). Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks, CA: Sage Publications Inc.

Titel: Assessment of Parkinson’s disease levodopa-induced dyskinesia: a qualitative research study
verfasst von: William R. Lenderking
Sally Mannix
Jennifer Petrillo
Christopher Kenney
Amanda Landrian
Anette-Eleonore Schrag
Publikationsdatum: 01.08.2015
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 8/2015
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-015-0925-7

Springer Medizin

Abstract

Background and objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Erratum to: 21st Annual Conference of the International Society for Quality of Life Research

Validity of the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) in individuals with Huntington disease (HD)

Validation of the chronic respiratory questionnaire in the Colombian population with chronic obstructive pulmonary disease

The correlation of the “Walking Estimated-Limitation Calculated by History” (WELCH) questionnaire with treadmill maximal walking time is not impaired by age, in patients with claudication

Short Musculoskeletal Function Assessment: normative data of the Dutch population

Testing item response theory invariance of the standardized Quality-of-life Disease Impact Scale (QDIS®) in acute coronary syndrome patients: differential functioning of items and test